Elgible paients were given 300 mg TDF daily befoe breakfast. Treatment duration was for 4 years. Enrolled patients were seen in out patient ever 12 week basis. Complete blood cell count, ALT, urea, creatinine

and HBV-DNA Rquantitative was done every 12 week basis. HBV-DNA <60 IU/ml was considered complete virological response (VR). Results: Results: We are reporting 36 months treatment results of this cohort. Median age at baseline was 45, 60% were male and 40% were female, 70% were HBeAg negative. Mean HBV-DNA was 6 log IU/ml, mean ALT was 80. Virological response (VR) was 70%, 85% and 90% at 12, 24 and 36 months respectively. There were no significat Erlotinib clinical trial side effects especially no abnormal renal function. These patienst are continuing this treatment for another 12 months. Conclusion: Conclusion: TDF shows significant and sustained antiviral activity against HBV. It has a very favorable safety profile. Key Word(s): 1. tenofovir; 2. chronic hepatitis B; 3. naive patients; Presenting 3MA Author: MUZAFFAR GILL Additional Authors: UZMA GILL, HAFSA AZIZ, FARAH SALMAN Corresponding Author: MUZAFFAR GILL Objective: Background: Entecavir is one of the most commonly used nucleo(s) tide

analogue in the treatment of chronic Hep B patients. we are using this product in our practice for the last 5 years now. We wanted to study the efficacy and safety of this compound in treatment eligible chronic

HBV patients. Methods: Methods: we prospectively enrolled 100 treatment Selleckchem Sorafenib naive patients with chronic HBV. Enrollment period was from january 2008 to june 2008. patients with Hep B surface antigen positive, ALT >80 and HBV-DNA >20, 000 IU/ml were included this study Patients with established diagnosis of cirrhosis were excluded from this study. Elgible paients were given 0.5 mg Entecavir daily befoe breakfast. Treatment duration was for 4 years. Enrolled patients were seen in ou t patient basis at every 12 week.Complete blood cell count, ALT, urea, creatinine and HBV-DNA quantitative was done every 12 week basis. HBV-DNA <60 IU/ml was considered complete virological response (VR). Results: Results: We are reporting 36 months treatment results of this cohort.Median age at baseline was 40, 60% were male and 40% were female, 70% were HBeAg negative. Mean HBV-DNA was 6 log IU/ml, mean ALT was 80.Virological response (VR) was 70%, 80% and 90% at 12, 24 and 36 months respectively.There were no significat side effects especially no abnormal renal function.These patienst are continuing this treatment for another 12 months. Conclusion: Conclusion: Entecavir shows significant and sustained antiviral activity against HBV. It has a very favorable safety profile. Key Word(s): 1. chronic hepatitis B; 2.